Table 1.
CASH screening log of cavernoma cases excluded for various reasons for: (A) Screening and Clinical Assessment (SCA), and (B) Follow-up and Biomarker Validation (FUBV) studies, by recruitment site and overall between August 2018 – March 2020.
| A) SCA study | |||||||
|---|---|---|---|---|---|---|---|
| BNI | Mayo | UNM | Utah | UCSF | UoC | Overall | |
| Exclusion criteria* | n=144 | n=235 | n=140 | n=68 | n=73 | n=189 | n=849 |
| <18 years old | 2% | 2% | 16% | 0% | 4% | 7% | 6% |
| No brain CA diagnosis | 2% | 5% | 1% | 13% | 0% | 0% | 3% |
| No symptomatic hemorrhage in past year | 67% | 69% | 89% | 70% | 70% | 70% | 72% |
| Unable to provide consent | 5% | 2% | 1% | 9% | 6% | 2% | 3% |
| Lesion located in spine | 3% | 11% | 1% | 0% | 1% | 1% | 4% |
| Prior brain irradiation | 3% | 8% | 4% | 1% | 4% | 2% | 4% |
| Verification of symptomatic hemorrhage impossible | 1% | 2% | 0% | 1% | 6% | 0% | 1% |
| Prior/planned surgery of CA | 29% | 12% | 5% | 9% | 35% | 5% | 14% |
| B) FUBV study | |||||
|---|---|---|---|---|---|
| Mayo | UNM | UCSF | UofC | Overall | |
| Exclusion Criteria* | n=218 | n=139 | n=1 | n=184 | n=542 |
| Unwilling/unable to do MRI | 0% | 0% | 0% | 2% | 1% |
| Pregnant/breastfeeding | 0% | 1% | 0% | 2% | 1% |
| Unlikely/unwilling to return for follow-up | 14% | 1% | 0% | 1% | 6% |
*
Percentages for criterion are not mutually exclusive. BNI: Barrow Neurological Institute, Mayo: Mayo Clinic Rochester, UNM: University of New Mexico, Utah: University of Utah, UCSF: University of California San Francisco, UofC: University of Chicago, CA: cavernous angioma